Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

PURPOSE: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimens in double-hit lymphoma (DHL) and gene copy number g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Ma, Qianwen, Chang, Yu, Li, Ling, Li, Xin, Wang, Xinhua, Wu, Jingjing, Fu, Xiaorui, Sun, Zhenchang, Yu, Hui, Zhang, Xudong, Zhou, Zhiyuan, Nan, Feifei, Li, Zhaoming, Liu, Xiyang, Zhao, Qian, Li, Yang, Zhang, Lan, Zhang, Mingzhi, Zhang, Lei
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6376881/
https://ncbi.nlm.nih.gov/pubmed/30809101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S192143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados